(Q37710237)

22 August 2017

1 reference

title

Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain (English)

1 reference

22 August 2017

1 reference

1 reference

Lara K Ellinger

1

1 reference

22 August 2017

Heather J Ipema

series ordinal

2

1 reference

22 August 2017

Joan M Stachnik

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

16 March 2010

1 reference

Annals of Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

44

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

668-679

1 reference

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

22 August 2017

cites work

1 reference

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

Options for pharmacological management of obesity in patients treated with atypical antipsychotics.

21 January 2018

1 reference

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

Current options in the management of olanzapine-associated weight gain

21 January 2018

1 reference

National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

21 January 2018

1 reference

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

An overview of obesity in children with psychiatric disorders taking atypical antipsychotics

21 January 2018

1 reference

Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain?

21 January 2018

1 reference

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

21 January 2018

1 reference

Amantadine for weight gain associated with olanzapine treatment

21 January 2018

1 reference

Open label study of the effect of amantadine on weight gain induced by olanzapine

21 January 2018

1 reference

Effect of amantadine on weight gain during olanzapine treatment

21 January 2018

1 reference

Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series

21 January 2018

1 reference

The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients

21 January 2018

1 reference

Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial

21 January 2018

1 reference

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study

21 January 2018

1 reference

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

21 January 2018

1 reference

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

21 January 2018

1 reference

Memantine-associated reversal of clozapine-induced weight gain

21 January 2018

1 reference

Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.

21 January 2018

1 reference

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study

21 January 2018

1 reference

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial

21 January 2018

1 reference

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial

21 January 2018

1 reference

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine

21 January 2018

1 reference

Metformin for weight control in pediatric patients on atypical antipsychotic medication.

21 January 2018

1 reference

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report.

21 January 2018

1 reference

An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects

21 January 2018

1 reference

Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient

21 January 2018

1 reference

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain

21 January 2018

1 reference

Nizatidine for the treatment of patients with quetiapine-induced weight gain

21 January 2018

1 reference

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study

21 January 2018

1 reference

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

21 January 2018

1 reference

Orlistat in the treatment of psychopharmacologically induced weight gain.

21 January 2018

1 reference

Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain

21 January 2018

1 reference

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

21 January 2018

1 reference

Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial

21 January 2018

1 reference

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

21 January 2018

1 reference

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study

21 January 2018

1 reference

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

21 January 2018

1 reference

Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation

21 January 2018

1 reference

Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial

21 January 2018

1 reference

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia

21 January 2018

1 reference

Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders

21 January 2018

1 reference

Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.

21 January 2018

1 reference

Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review

21 January 2018

1 reference

Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate

21 January 2018

1 reference

Topiramate for reversing atypical antipsychotic weight gain

21 January 2018

1 reference

Metformin-associated lactic acidosis: a prognostic and therapeutic study.

21 January 2018

1 reference

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

Role of metformin for weight management in patients without type 2 diabetes

21 January 2018

1 reference

Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies

21 January 2018

1 reference

Interventions to reduce weight gain in schizophrenia

21 January 2018

1 reference

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M550

1 reference

22 August 2017

1 reference